Health Economics in the Canadian Pharmaceutical Industry
- 38 Downloads
Objective: To assess the goals, strategic focus, structure, capabilities, activities and effectiveness of health economics (HE) departments in the Canadian pharmaceutical industry, to examine how these have evolved, and the implications of HE in the future of the pharmaceutical industry.
Design and Interventions: A mixture of telephone and face-to-face interviews with members of the HE unit (survey 1) and the chief executive officers (CEOs) [survey 2] of the top 21 Canadian pharmaceutical companies was undertaken in 1997.
Main outcome measures and results: 17 out of 21 companies responded to the first survey, and 12 of the 17 CEOs responded to our second survey. The goals of the HE department in most of the pharmaceutical companies have evolved from supporting efforts to gain reimbursement on government drug plans to include pricing, promotion, internal decision-making and other activities. Members of the HE department perceive their work to be valuable to the company. The CEOs felt that the true value of HE data is not adequately understood by formulary reviewers and, therefore, HE data may be an impediment to market access.
Conclusions: The purpose of the HE department is to demonstrate the value of the company’s product to provincial government insurers. However, pharmaceutical companies are having difficulty justifying the importance of the HE department because of inconsistencies in the interpretation of economic evaluations by healthcare payers.
KeywordsAdis International Limited Economic Evaluation Chief Executive Officer Market Access Head Office
Unable to display preview. Download preview PDF.
- 1.MacDonald F. Strategic use for pharmacoeconomics in the early stages of drug development. ADrug Information Association Workshop on Health Economics Presentation: The Impact of Economic Evaluation on New Drug Development and Marketing: 1993 Nov 14–17; LisbonGoogle Scholar
- 2.Walker S. Socioeconomic evaluation of medicines: a survey of the global pharmaceutical industry. A Drug Information Association Workshop on Health Economics Presentation: The Impact of Economic Evaluation on New Drug Development and Marketing: 1993 Nov 14–17; LisbonGoogle Scholar
- 3.Kunze ZM, Lumley CE, Walker SR. Socioeconomic evaluation of medicines: a survey of the international pharmaceutical industry. Surrey: Centre for Medicines Research International, 1993: 2–32Google Scholar
- 6.Favourable reimbursement for CNS drugs no longer guaranteed. PharmacoEcon Outcomes News 1998; 165: 11Google Scholar
- 7.Carmine B. Update and evaluation of Australian guidelines: industry perspective. Med Care 1996 34: DS226–32Google Scholar
- 8.Mitchell A. Update and evaluation of Australian guidelines: government perspective. Med Care 1996; 34: DS216–25Google Scholar
- 11.Mandelkar J. Outcomes: the science of prescribing. Bus Health 1995; 13: 28–30Google Scholar
- 14.Todd C. What makes health economics research useful to decision-makers? Pharmaco Econ Outcomes News 1998; 170: 3–4Google Scholar
- 16.IMS Canada. IMS academic reference manual: Canadian health care information for pharmacy academics and students. Mississauga (ON): IMS Canada, 1997Google Scholar
- 17.Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceuticals: Canada. 1st ed. Ottawa (ON): CCOHTA, 1994Google Scholar
- 18.Ontario Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Toronto (ON): Queen’s Printer for Ontario, 1994Google Scholar